Mer­ck pumps the brakes on two more PhI­II tri­als for its lead an­ti-HIV drug

Af­ter tri­al in­ves­ti­ga­tors flagged a drop in im­mune cell counts that an ex­ter­nal com­mit­tee de­ter­mined was re­lat­ed to treat­ment last month, Mer­ck has been paus­ing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER